$GALT News Article - UPDATE -- Galectin Therapeutics Announces Commencement of Patient Enrollment of the Adaptively-Designed Phase 2b/3 Trial of Belapectin in NASH Cirrhosis https://marketwirenews.com/news-releases/upda...03312.html
(0)
(0)
Galectin Therapeutics Inc (GALT) Stock Research Links